Intech Investment Management LLC Has $26.31 Million Stake in Edwards Lifesciences Co. (NYSE:EW)

Intech Investment Management LLC boosted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 324.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 398,625 shares of the medical research company's stock after purchasing an additional 304,645 shares during the period. Intech Investment Management LLC owned 0.07% of Edwards Lifesciences worth $26,305,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Cetera Advisors LLC increased its stake in shares of Edwards Lifesciences by 175.1% in the 1st quarter. Cetera Advisors LLC now owns 38,090 shares of the medical research company's stock valued at $3,640,000 after buying an additional 24,242 shares during the period. BDF Gestion acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at $5,148,000. Tidal Investments LLC increased its stake in shares of Edwards Lifesciences by 54.7% in the 1st quarter. Tidal Investments LLC now owns 30,245 shares of the medical research company's stock valued at $2,890,000 after buying an additional 10,700 shares during the period. Raymond James & Associates increased its stake in shares of Edwards Lifesciences by 2.8% in the 2nd quarter. Raymond James & Associates now owns 1,825,230 shares of the medical research company's stock valued at $168,597,000 after buying an additional 50,124 shares during the period. Finally, AIA Group Ltd increased its stake in shares of Edwards Lifesciences by 91.7% in the 3rd quarter. AIA Group Ltd now owns 749,524 shares of the medical research company's stock valued at $49,461,000 after buying an additional 358,556 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business's stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now owns 46,936 shares of the company's stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 40,000 shares of company stock valued at $2,657,000. 1.29% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

EW has been the subject of several research reports. Morgan Stanley reissued an "equal weight" rating and issued a $70.00 target price on shares of Edwards Lifesciences in a research note on Friday, October 11th. Robert W. Baird reduced their price target on Edwards Lifesciences from $73.00 to $68.00 and set a "neutral" rating on the stock in a research report on Friday, October 25th. Oppenheimer restated an "outperform" rating and issued a $90.00 price target on shares of Edwards Lifesciences in a research report on Thursday, September 12th. Stifel Nicolaus reduced their price target on Edwards Lifesciences from $85.00 to $70.00 and set a "hold" rating on the stock in a research report on Thursday, July 25th. Finally, Citigroup reduced their price target on Edwards Lifesciences from $83.00 to $77.00 and set a "buy" rating on the stock in a research report on Tuesday, October 1st. Seventeen analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $75.67.

Edwards Lifesciences Price Performance

NYSE:EW opened at $69.54 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock's 50-day simple moving average is $67.61 and its 200 day simple moving average is $75.87. The company has a market cap of $41.01 billion, a P/E ratio of 10.03, a P/E/G ratio of 3.95 and a beta of 1.12. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.67. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences's quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.59 earnings per share. As a group, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.